Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients - Test2 - elhamkhani - TriplyDB

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

http://www.wikidata.org/entity/Q28257370

about

Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial Oxidative stress in schizophrenia N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action Using glutamate homeostasis as a target for treating addictive disorders Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia Oxidative pathways as a drug target for the treatment of autism Mechanisms of divalent metal toxicity in affective disorders Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia A Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and Progression Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia.Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia.Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia Mismatch negativity (MMN) as an index of cognitive dysfunction Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia.Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls.Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses.How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.Yi-gan san restores behavioral alterations and a decrease of brain glutathione level in a mouse model of schizophrenia Inhibitory interneurons, oxidative stress, and schizophrenia.Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia.Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia.Gray matter deficits, mismatch negativity, and outcomes in schizophrenia.N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?Research in people with psychosis risk syndrome: a review of the current evidence and future directions The relationship between preattentive sensory processing deficits and age in schizophrenia patients The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice.N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice Glutamatergic modulation of auditory information processing in the human brain.Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

P2860

Q21560890-4BB08E2E-A67B-4A2D-9996-F726CB915A15 Q24595660-BD7AD794-0AF4-430B-BAC1-546D9793DD8F Q24615952-CE37EB0B-A935-4C5E-BA52-6F66ABB69492 Q24619198-D5917EA6-A4EB-4C7E-BE84-8B5939EE41D3 Q26741541-3CD2C9C4-39FE-404B-9DBD-20E4CBA30C52 Q26786354-3936E7E0-9322-4959-9636-C6EC28793DED Q26864995-B8F4C3B5-885F-4DEF-B115-77DEFAF3903E Q27014120-96221130-7208-4BD0-BD57-F24750822DF4 Q28248117-E67C6781-A469-4A76-8940-4E657A87DABF Q28248687-E45B70BE-274A-4921-A68E-C4ACAEC2D857 Q28275290-0F11A88A-D7BC-4778-B4B7-13CBCE384417 Q28295948-AE5E6E9F-E107-47FF-976B-61E5C94A1A56 Q28384836-7D68935D-36C9-416E-9739-1B88035A1BD5 Q28472479-F943DC9B-4EEE-431B-93D0-8E64D7552DE7 Q28727584-78793880-687F-4E8C-BC5E-626F694701C9 Q30354141-4244DA6D-7378-48B4-93BF-17B2F60972DE Q30380519-CAE8F989-BADD-44EF-90FC-18FAD5A5B752 Q30384452-E2891F64-C9AF-4D8C-9812-4B192F63BABD Q30387378-8D392BA2-6FB8-49C9-9F09-1710B5460312 Q30394589-FB36AFA7-EF53-4025-97BB-9DD97379EB3C Q30403302-389AF57E-4891-4681-9C1C-836EAA96269D Q30403518-BBF9BE63-EBDE-49FA-9187-DF699050D891 Q30407708-7ABD542E-02CF-4E92-A8E4-890198078CB3 Q30426629-978EA526-FCD8-489B-A245-91D64E8183BC Q30439309-A1DD147D-6528-4209-95FF-65639C8A7AE3 Q30439826-473A7607-FD1F-41D5-B7D7-D967572BC664 Q30439924-E5F3E350-A99B-4816-8721-683D2D77F779 Q30452926-3DB7392B-74F2-4B07-829F-874014C1A1D1 Q30455112-8766F899-9DA4-48D9-9616-0F240761F1B5 Q30457809-B179038F-62C9-4BD8-98C2-61F6C4F023A6 Q30459211-1CABCC74-273F-45C9-AA08-1B5607984BC1 Q30463810-8ADE121B-E067-4C00-8B74-A837EC4D3A82 Q30471859-373D357E-828D-4897-9D78-21171FFE3F91 Q30474021-5C75A88A-D1D8-491F-8772-2FF9F3D90CBC Q30475598-0A7024F0-4D43-4082-8705-29712A1AF352 Q30478849-10627CB9-3F29-4F5C-9C07-54B7D68C6FEB Q30481854-5C6F289C-70F4-4770-824C-9DDBB7E4482E Q30504497-FCDEDF9C-D634-490E-A017-34C622438E25 Q30506046-5C4F0BF4-F525-4B6A-A0F9-05B2AD5FD585 Q33350202-33C0F7EB-F612-4B7B-955E-2F6880024390

P2860

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

http://www.wikidata.org/entity/Q28257370

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@ast

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@en

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@nl

type

label

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@ast

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@en

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@nl

prefLabel

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@ast

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@en

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@nl

P1433

Q28257370-CE775358-DE67-4CA6-A7A3-BF9A4CF3743E

P1476

Q28257370-71C3C1A0-34D6-4E40-A730-486ADD94D2E2

P2093

Q28257370-1616F910-CC39-4C21-999B-E34C1D313A61

Q28257370-262BC1A7-31AA-424F-BCEF-E063B250DA27

Q28257370-2AE39EF6-78C7-4A6F-BB4A-ABE76A973225

Q28257370-3201DA37-A300-4798-8B5C-AF1C93215757

Q28257370-4822A3BD-4EBC-4067-BB23-5469D5FEA7B7

Q28257370-4B6264E7-39E8-4CDD-936B-C6D251B69B8D

Q28257370-9947DF28-65F2-40D9-B98F-8A93ED44AC18

Q28257370-B608AF32-AC32-43C2-B6CA-33EA861071A6

Q28257370-B70C8FF6-A4BB-4ABA-A80C-932CF5964DE3

Q28257370-D88AACB7-3665-49C8-8704-FE3AD8CB033B

P2860

Q28257370-0054F526-917C-4BC0-9F85-0CEEE50E423D

Q28257370-07E22150-1BA3-41CF-A41F-589040AE08F9

Q28257370-08CDB301-3598-46FB-BFE0-63E4475E4898

Q28257370-0E78E7B4-55A6-41AF-8492-6377E451FA08

Q28257370-141465C3-22D1-4375-A038-12AE513E6FD9

Q28257370-241DEA1A-6850-46AE-8D6B-BE34D2D55BE5

Q28257370-2E628B4E-ED1D-4A49-90BC-6888FBB97A05

Q28257370-334CE511-DF37-43CD-9C05-EE789D18BF72

Q28257370-4035674E-1D80-46B6-BEBB-823EFF4E6078

Q28257370-5036D68E-B733-4FE4-ADCC-CE2EFAE3B367

P2888

Q28257370-0423CD49-BD77-4C2E-BEDC-9498C24D4F02

P304

Q28257370-2FB584DD-769F-430E-9947-B7C3219938A5

P31

Q28257370-7CCEC462-2A9B-4569-ADDC-EF8E86235F2D

P3181

Q28257370-4D7EA498-E18D-4119-9E8B-1A8CD8D1F429

P356

Q28257370-85ACDFA9-3533-4C91-98E3-FFF50E136069

P407

Q28257370-A904F6A3-77FB-4C67-8412-4DFBC617CC36

P433

Q28257370-38C46387-8F98-46F9-8499-A0D5A6CF2CA5

P478

Q28257370-F3EC5C82-B5C1-4010-BFFF-9E33730C5285

P50

Q28257370-3590F286-E400-4CE7-87A5-50332FB99AE5

Q28257370-415F809F-9F20-49ED-AB3A-6546AD7C9625

Q28257370-B31675E0-6255-4E45-BFC5-86241A549E7E

Q28257370-D5B610BF-4119-4501-AA08-3A3A1A31664E

Q28257370-FB4D2498-5985-4F95-B3D2-A4741B13B56D

P577

Q28257370-D7400D2C-684B-467E-B039-BF1B1BFC096D

P5875

Q28257370-91AF9969-075A-4040-A6AD-5B80E4B77C1A

P6179

Q28257370-5A513F52-D083-46F0-910A-EE20FEE5E814

P698

Q28257370-54806108-63C0-42C0-8B52-38AE334E5582

P921

Q28257370-AC5885A1-46BA-45DA-B69B-6D1730EB5E62

P3181

P356

P1433

Neuropsychopharmacology

P1476

Glutathione precursor, N-acety ...... vity in schizophrenia patients

@en

P2093

Alessandra Solida

http://www.w3.org/2001/XMLSchema#string

David Copolov

http://www.w3.org/2001/XMLSchema#string

Eleonora Fornari

http://www.w3.org/2001/XMLSchema#string

Maria G Knyazeva

http://www.w3.org/2001/XMLSchema#string

Michel Cuénod

http://www.w3.org/2001/XMLSchema#string

Olivier Boulat

http://www.w3.org/2001/XMLSchema#string

Pascal Vianin

http://www.w3.org/2001/XMLSchema#string

Patricia Deppen

http://www.w3.org/2001/XMLSchema#string

Philippe Conus

http://www.w3.org/2001/XMLSchema#string

Pierre Bovet

http://www.w3.org/2001/XMLSchema#string

P2860

Early selective-attention effect on evoked potential reinterpreted

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

Recent advances in the phencyclidine model of schizophrenia

Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia

Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures

Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering.

EEG source imaging.

Glutamate and schizophrenia: beyond the dopamine hypothesis.

Redox modulation of the NMDA receptor.

P2888

P304

2187-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3479570

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.NPP.1301624

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Micah M. Murray

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5843296

http://www.w3.org/2001/XMLSchema#string

P6179

1011937964

http://www.w3.org/2001/XMLSchema#string

P698

18004285

http://www.w3.org/2001/XMLSchema#string

P921